Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

R. M. Stone, T. Fischer, R. Paquette, G. Schiller, C. A. Schiffer, G. Ehninger, J. Cortes, H. M. Kantarjian, D. J. Deangelo, A. Huntsman-Labed, C. Dutreix, A. Del Corral, F. Giles

Research output: Contribution to journalArticle

Abstract

This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen. The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)). Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, respectively) were similar to the FLT3-wild-type population (0.78 and 0.52, respectively). Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days. A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).

Original languageEnglish (US)
Pages (from-to)2061-2068
Number of pages8
JournalLeukemia
Volume26
Issue number9
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

4'-N-benzoylstaurosporine
Receptor Protein-Tyrosine Kinases
Acute Myeloid Leukemia
Phosphotransferases
Drug Therapy
Appointments and Schedules
Cytarabine
Daunorubicin
Nausea
Vomiting
Young Adult
Survival Rate
Survival

Keywords

  • acute myeloid leukemia
  • FMS-like tyrosine kinase 3 receptor
  • midostaurin
  • newly diagnosed
  • PKC412

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Stone, R. M., Fischer, T., Paquette, R., Schiller, G., Schiffer, C. A., Ehninger, G., ... Giles, F. (2012). Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia, 26(9), 2061-2068. https://doi.org/10.1038/leu.2012.115

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. / Stone, R. M.; Fischer, T.; Paquette, R.; Schiller, G.; Schiffer, C. A.; Ehninger, G.; Cortes, J.; Kantarjian, H. M.; Deangelo, D. J.; Huntsman-Labed, A.; Dutreix, C.; Del Corral, A.; Giles, F.

In: Leukemia, Vol. 26, No. 9, 09.2012, p. 2061-2068.

Research output: Contribution to journalArticle

Stone, RM, Fischer, T, Paquette, R, Schiller, G, Schiffer, CA, Ehninger, G, Cortes, J, Kantarjian, HM, Deangelo, DJ, Huntsman-Labed, A, Dutreix, C, Del Corral, A & Giles, F 2012, 'Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia', Leukemia, vol. 26, no. 9, pp. 2061-2068. https://doi.org/10.1038/leu.2012.115
Stone, R. M. ; Fischer, T. ; Paquette, R. ; Schiller, G. ; Schiffer, C. A. ; Ehninger, G. ; Cortes, J. ; Kantarjian, H. M. ; Deangelo, D. J. ; Huntsman-Labed, A. ; Dutreix, C. ; Del Corral, A. ; Giles, F. / Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. In: Leukemia. 2012 ; Vol. 26, No. 9. pp. 2061-2068.
@article{52e4475e3c5e4aa3a75d6eb5c082efb8,
title = "Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia",
abstract = "This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen. The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80{\%} (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74{\%}), FLT3-mutant: 12 of 13 (92{\%})). Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, respectively) were similar to the FLT3-wild-type population (0.78 and 0.52, respectively). Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days. A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).",
keywords = "acute myeloid leukemia, FMS-like tyrosine kinase 3 receptor, midostaurin, newly diagnosed, PKC412",
author = "Stone, {R. M.} and T. Fischer and R. Paquette and G. Schiller and Schiffer, {C. A.} and G. Ehninger and J. Cortes and Kantarjian, {H. M.} and Deangelo, {D. J.} and A. Huntsman-Labed and C. Dutreix and {Del Corral}, A. and F. Giles",
year = "2012",
month = "9",
doi = "10.1038/leu.2012.115",
language = "English (US)",
volume = "26",
pages = "2061--2068",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

AU - Stone, R. M.

AU - Fischer, T.

AU - Paquette, R.

AU - Schiller, G.

AU - Schiffer, C. A.

AU - Ehninger, G.

AU - Cortes, J.

AU - Kantarjian, H. M.

AU - Deangelo, D. J.

AU - Huntsman-Labed, A.

AU - Dutreix, C.

AU - Del Corral, A.

AU - Giles, F.

PY - 2012/9

Y1 - 2012/9

N2 - This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen. The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)). Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, respectively) were similar to the FLT3-wild-type population (0.78 and 0.52, respectively). Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days. A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).

AB - This phase 1b trial investigated several doses and schedules of midostaurin in combination with daunorubicin and cytarabine induction and high-dose cytarabine post-remission therapy in newly diagnosed patients with acute myeloid leukemia (AML). The discontinuation rate on the 50-mg twice-daily dose schedule was lower than 100 mg twice daily, and no grade 3/4 nausea or vomiting was seen. The complete remission rate for the midostaurin 50-mg twice-daily dose schedule was 80% (FMS-like tyrosine kinase 3 receptor (FLT3)-wild-type: 20 of 27 (74%), FLT3-mutant: 12 of 13 (92%)). Overall survival (OS) probabilities of patients with FLT3-mutant AML at 1 and 2 years (0.85 and 0.62, respectively) were similar to the FLT3-wild-type population (0.78 and 0.52, respectively). Midostaurin in combination with standard chemotherapy demonstrated high complete response and OS rates in newly diagnosed younger adults with AML, and was generally well tolerated at 50 mg twice daily for 14 days. A phase III prospective trial is ongoing (CALGB 10603, NCT00651261).

KW - acute myeloid leukemia

KW - FMS-like tyrosine kinase 3 receptor

KW - midostaurin

KW - newly diagnosed

KW - PKC412

UR - http://www.scopus.com/inward/record.url?scp=84865865542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865865542&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.115

DO - 10.1038/leu.2012.115

M3 - Article

C2 - 22627678

AN - SCOPUS:84865865542

VL - 26

SP - 2061

EP - 2068

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -